Bronchoscopy is the most important tool in diagnosing respiratory disorders. Diagnostic indications are numerous and range from bronchial wash or bronchoalveolar lavage, in case of pulmonary infiltrations, to transbronchial lung biopsies in peripheral solitary pulmonary nodules. Different techniques, such as peripheral endobronchial ultrasound probes, or different navigation systems facilitate diagnosis of peripheral pulmonary lesions. Furthermore, endobronchial-guided transbronchial needle aspiration gained increased significance for mediastinal staging in lung cancer patients. Bronchoscopy also offers many therapeutic modalities. In case of haemoptysis, cold saline lavage, instillation of topical vasoconstrictive agents, endobronchial airway blockade, laser therapy, argon plasma coagulation and electrocautery present useful tools. Another indication for therapeutic bronchoscopy is a central airway obstruction resulting from benign or malignant processes. Rapid symptom control can be achieved by laser-assisted resection, electrocautery and cryodebridement. Furthermore, the insertion of an airway stent re-establishes the patency of obstructed airways. Brachytherapy is another treatment option for malignant airway stenoses. Due to its delayed effects, brachytherapy should only be considered in respiratorily stable patients. Recently developed therapeutic modalities are endoscopic lung volume reduction in patients with chronic obstructive pulmonary disease and bronchial thermoplasty in patients with asthma.
Share this Article
Related Content In Lung Cancer
MET Exon 14 Skipping Alterations in NSCLC: Current Understanding and Therapeutic Advances
Oncology & Hematology Review (US). 100-10 DOI: https://doi.org/10.17925/OHR.2021.16.2.100
Advanced non-small cell lung carcinoma (NSCLC) treatment paradigms have evolved during the past decade. Identification of tumor-specific molecular alteration in cancer driver genes has led to the development of targeted therapies.1–3 Most of the tumors harboring such alterations are sensitive to tyrosine kinase inhibitor (TKI) drugs, making such oncogenic drivers promising targets for the development of […]
Radiation-induced Esophagitis in Lung Cancer—A Common Problem with Limited Therapeutic Options
Oncology & Hematology Review. 2020;16(2): 95-99 DOI: https://doi.org/10.17925/OHR.2021.16.2.95
Radiation-induced esophagitis, caused by incidental damage to the mucosal lining of the esophagus during radiation therapy, is a common and clinically important toxicity in patients with lung cancer. Esophagitis generally develops 2–3 weeks after initiation of radiation therapy and presents as pain and dysphagia, which can negatively impact patient quality of life.1 Severe esophagitis requires parenteral […]
Facing the First-line in Metastatic Non-small-cell Lung Cancer – Immunotherapy and Chemotherapy
European Oncology & Haematology. 2020;16(1):39-43 DOI: https://doi.org/10.17925/EOH.2020.16.1.39
Historically, chemotherapy represented the only available treatment for patients with advanced non-small-cell lung cancer (NSCLC) who did not show any target molecular driver, such as epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK) or the receptor tyrosine kinase ROS1. Unfortunately, limited efficacy was reported using chemotherapy alone.1 The advent of immunotherapy, a treatment based on […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!